Alignment Healthcare, Inc. (NASDAQ:ALHC) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) have received a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $24.5556.

Several research analysts have issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Alignment Healthcare in a report on Wednesday, January 21st. UBS Group upped their price objective on shares of Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, January 14th. Piper Sandler increased their price objective on shares of Alignment Healthcare from $20.00 to $30.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 6th. Robert W. Baird set a $28.00 target price on shares of Alignment Healthcare in a research note on Friday, January 30th. Finally, KeyCorp restated an “overweight” rating and issued a $28.00 target price on shares of Alignment Healthcare in a report on Thursday, January 22nd.

Insider Transactions at Alignment Healthcare

In related news, CEO John E. Kao sold 605,648 shares of the company’s stock in a transaction dated Monday, December 29th. The stock was sold at an average price of $18.74, for a total transaction of $11,349,843.52. Following the sale, the chief executive officer owned 2,234,294 shares in the company, valued at $41,870,669.56. This represents a 21.33% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Robert L. Scavo sold 69,541 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The stock was sold at an average price of $18.74, for a total value of $1,303,198.34. Following the sale, the insider directly owned 503,014 shares of the company’s stock, valued at $9,426,482.36. This represents a 12.15% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 2,418,393 shares of company stock valued at $46,473,667. Corporate insiders own 6.60% of the company’s stock.

Hedge Funds Weigh In On Alignment Healthcare

Several institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP raised its position in shares of Alignment Healthcare by 8.9% during the fourth quarter. Allworth Financial LP now owns 6,917 shares of the company’s stock worth $137,000 after purchasing an additional 566 shares during the period. State of Alaska Department of Revenue lifted its holdings in shares of Alignment Healthcare by 6.0% in the 4th quarter. State of Alaska Department of Revenue now owns 11,296 shares of the company’s stock worth $223,000 after purchasing an additional 636 shares in the last quarter. Integrated Wealth Concepts LLC grew its position in Alignment Healthcare by 6.3% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 11,230 shares of the company’s stock valued at $196,000 after purchasing an additional 665 shares during the period. Parallel Advisors LLC grew its position in Alignment Healthcare by 87.7% in the 4th quarter. Parallel Advisors LLC now owns 1,654 shares of the company’s stock valued at $33,000 after purchasing an additional 773 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its stake in Alignment Healthcare by 2.3% during the 3rd quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 37,752 shares of the company’s stock valued at $659,000 after purchasing an additional 844 shares in the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.

Alignment Healthcare Trading Down 0.5%

Shares of ALHC stock opened at $17.42 on Wednesday. The stock has a market cap of $3.56 billion, a price-to-earnings ratio of -1,740.26, a PEG ratio of 2.56 and a beta of 1.18. The stock has a 50-day moving average of $20.30 and a 200-day moving average of $18.84. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. Alignment Healthcare has a 1-year low of $11.63 and a 1-year high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The company had revenue of $1.01 billion for the quarter, compared to analyst estimates of $1 billion. During the same period in the previous year, the firm earned ($0.16) earnings per share. The firm’s quarterly revenue was up 44.4% on a year-over-year basis. On average, equities research analysts forecast that Alignment Healthcare will post -0.69 earnings per share for the current year.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.